EMA Awards Orphan Drug Designation to NanoViricides's DengueCide

Published November 14, 2013

EMA Awards Orphan Drug Designation to NanoViricides's DengueCide
[rewrite]NanoViricides, Inc. (the "Company") announced today that the European Medicines Agency (EMA), has awarded orphan drug designation to DengueCide™, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. Dengue Fever …[/rewrite]
Read more on AZoNano.com

13 free agents decline qualifying offers
[rewrite]Cruz served a 50-game suspension from Major League Baseball for violating the league's Joint Drug Prevention and Treatment Program. The ban stemmed from the league's investigation of South Florida anti-aging clinic Biogenesis. –Cincinnati Reds …[/rewrite]
Read more on Lyndy’s Sports Annuals

Find More Drug Treatment Programs Florida Information…